2018 SITC: Molecular Profiling of Anti-PD-1 Treated Melanoma Patients Reveals Importance of Assessing Neoepitope Burden and Tumor Escape Mechanisms for Clinical Treatment

Despite the remarkable response of some melanoma patients to checkpoint inhibitor therapy, significant numbers of patients do not achieve complete response. It is of great interest to identify biomarkers and mechanisms that influence immunotherapy effectiveness. Here we apply our comprehensive tumor immuno-genomics platform (ImmunoID NeXT) to identify potential biomarkers of response to checkpoint blockade therapy related to both the tumor and tumor microenvironment.